Enzomenib
Enzomenib is an investigational new drug that is being evaluated for the treatment of acute leukemia. It is a small molecule inhibitor that targets the interaction between menin and mixed-lineage leukemia proteins. Enzomenib particularly in patients with KMT2A rearrangements or NPM1 mutations.
The U.S. Food and Drug Administration has granted both Fast Track and Orphan Drug designations to Enzomenib.